BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

講師

全福生物科技股份有限公司

 

Company Info

Name /BRIM Biotechnology, Inc.

Address /No. 1, Alley 30, Lan3 358, Ruiguang Rd., Neihu Dict., Taipei 11492, Taiwan

Website /www.brimbiotech.com

Presenter

Name /Yi-Lun Chiang

Title /Business Development Manager

Email /yilun.chiang@brimbiotech.com

Telephone /02-2659-8586 #120

Fax /

Mobile /

Company Type

Biotechnology

About the Company

BRIM Biotechnology, Inc. applys integrated and efficient translational science to develop new treatments that help combat and cure disease. Our extensive experience and successful track record of translating discovery research to the clinic enables us to find and incubate high-potential novel drug candidates through our unique drug development engine to deliver partner-ready clinical assets.

Brief Description of main products or services

The key drug candidate is a synthetic peptide composed of 29 amino acids derived from a multi-functional protein, Pigment Epithelium-Derived Factor (PEDF), with neurotrophic and anti-inflammation properties. The functional domain of PEDF chosen to generate PEDF-derived short peptides (PDSP) also has a unique mechanism of action that can promote the “stemness” of certain types of stem cells, including mesenchymal stem cells. These properties allow PDSPs to be applied to a broad range of diseases that require faster tissue repair.

BRIM currently has 3 first-in-class, disease-modifying lead assets developed from the stem cell regenerative PDSP platform, i.e. BRM421 for Dry Eye Syndrome (DES), BRM424 for Neurotrophic Keratitis, and BRM521 for osteoarthritis.

Particularly in the eyes, this unique mechanism of action stimulates the proliferation and differentiation of corneal limbal stem cells, which as a result, speeds up corneal repair and heals ocular wounds in DES patients. BRM421 has shown promising clinical outcomes in two phase 2 studies with superior safety profiles. With encouraging efficacy and favorable safety profiles, BRM421 may enter a phase 3 study by the end of 2022.

Contact Person

Name /Yi-Lun Chiang

Email /yilun.chiang@brimbiotech.com

Phone /02-2659-8586 #120